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Inhibition of transcription factors (TF) that drive tumor
progression and immune evasion, such as STAT3, remains
a challenge for pharmacological drugs. Blocking STAT3
binding to DNA using specific decoy oligodeoxynucleo-
tides (dODN) provides an alternative targeted inhibitory
strategy. To achieve STAT3 inhibition specifically in anti-
gen-presenting cells, we linked STAT3dODN to a TLR9
ligand, CpG ODN as successfully done before for delivery
of siRNA molecules [1,2]. The CpG-STAT3dODN conju-
gates are quickly internalized by both human and mouse
TLR9-positive target cells, such as dendritic cells (DCs),
macrophages and B lymphocytes as well as by myeloid leu-
kemia and B lymphoma cells. In contrast, the uptake of
unconjugated decoy molecules by immune cells was mini-
mal as expected. After uptake, CpG-STAT3dODN mole-
cules bind and sequester activated STAT3 proteins,
thereby inhibiting their transcriptional activity as verified
using confocal microscopy, gel retardation and reporter
gene assays. The hairpin design and partial phosphor-
othioation of the backbone increases half-life of the CpG-
STAT3dODN in human serum to over 48 h. Therefore,
we assessed the feasibility of using CpG-STAT3dODNs
for systemic administration against disseminated human
TLR9+ acute myeloid leukemia (AML). As shown in xeno-
transplanted MV4-11 AML model, repeated daily intrave-
nous injections of CpG-STAT3dODN (5 mg/kg) resulted
in potent and direct antitumor effects. CpG-STAT3-
dODN, but not control conjugates, effectively eliminated
leukemic cells from all tested organs including bone mar-
row within two weeks from the initiation of the study. The
antitumor efficacy of this strategy is greatly enhanced in
immunocompetent mice. Systemic administration of
CpG-STAT3dODN induced regression of the syngeneic
mouse Cbfb/MYH11 leukemia from blood, spleen and
bone marrow within 12 days of treatment (Figure 1A).
The two pronged, cytotoxic and immunostimulatory
effects of this strategy resulted in long-term survival of
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the majority of mice (Figure 1B). The potent immune
activation was associated with enhanced expression of
antigen-presenting and co-stimulatory molecules not
only on the surface of DCs but also on differentiating
AML cells. These immunostimulatory effects correlated
with activation and infiltration of CD8+ T cells into var-
ious organs with concomitant reduction in regulatory
T cell numbers. Our findings highlight the potential of
using CpG-STAT3dODN for the two-pronged TLR9/
STAT3-targeted immunotherapy of human AML and
potentially other TLR9-positive blood cancers.
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